**To the Editor:** *Acinetobacter baumannii* is an opportunistic pathogen that is a source of nosocomial infections, mostly pneumonia ([@R1]). Treatment of infections caused by *A. baumannii* is becoming a serious clinical concern as this microorganism becomes increasingly resistant to multiple antimicrobial drugs ([@R2]). *A. baumannii* resistance to carbapenems is mostly associated with production of carbapenem-hydrolyzing class D β-lactamases and metallo-β-lactamases ([@R2]). New Delhi metallo-β-lactamase 1 (NDM-1) is one of the most recently discovered metallo-β-lactamases among various gram-negative species, including *A. baumannii* ([@R3]). We recently reported the recovery of NDM-1--producing *A. baumannii* isolates throughout Europe ([@R4]). In that study, the genetic background of several strains was identified and corresponded to sequence types (STs) 1, 25 and 85. The ST85 clone was isolated in France from 2 patients previously hospitalized in Algeria ([@R4],[@R5]).

The present study was initiated by the recent isolation of 6 more NDM-1--producing *A. baumannii* linked with North Africa. To determine the extent of spread of this organism from Africa to France, we genetically analyzed 8 other NDM-1-producing *A. baumannii* isolates collected from different towns in France during 2011--2012. Of these 8 isolates, 6 were from patients previously hospitalized in different cities in Algeria (including Algiers, Setif, Constantine, and Tlemcen), 1 from a patient previously hospitalized in Tunisia, and 1 from a patient previously hospitalized in Egypt. These 8 isolates came from 2 clinical samples (blood cultures and wound) from 6 screening rectal swab samples collected at the time of hospital admission ([Technical Appendix](#SD1){ref-type="local-data"}). Because the 8 samples were recovered from 5 hospitals, nosocomial acquisition can be ruled out.

The isolates were identified by 16S rRNA gene sequencing. Susceptibility testing was performed by disk diffusion (Sanofi-Diagnostic Pasteur, Marnes-La-Coquette, France) and interpreted according to updated Clinical and Laboratory Standards Institute guidelines ([@R6]). The MICs of β-lactams (imipenem, meropenem and doripenem) were determined by the Etest technique (AB bioMérieux, Solna, Sweden) according to the manufacturer's recommendations. All isolates were resistant to β-lactams, including all carbapenems (MICs \>32mg/L). The isolates were also resistant to fluoroquinolones, gentamicin, sulfonamides, and chloramphenicol but susceptible to amikacin, netilmicin, rifampin, tetracycline, and tigecycline according to Clinical and Laboratory Standards Institute guidelines ([@R6]) and colistin according to European Committee on Antimicrobial Susceptibility Testing guidelines ([www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf.pdf](www.eucast.org/fileadmin/src/media/PDFs/EUCAST_files/Disk_test_documents/EUCAST_breakpoints_v1.3_pdf.pdf)).

The production of metallo-β-lactamases was suspected by use of a combined disk test, based on the inhibition of the metallo-β-lactamase activity by EDTA as described ([@R4]). All isolates were positive for production of metallo-β-lactamases.

For all 8 isolates, PCRs aimed at detecting carbapenemase genes, using primers described elsewhere ([@R7]), followed by sequencing, led to identification of the *bla*~NDM-1~ gene. The isolates also carried a naturally-occurring *bla*~OXA-51~-like gene, namely *bla*~OXA-94~ ([Technical Appendix](#SD1){ref-type="local-data"}). The *bla*~OXA-51-like~ β-lactamase confers a low level of resistance to carbapenems.

Genotypic comparison was performed by multilocus sequence typing as described ([@R8]) and by repetitive extragenic palindromic sequence-based PCR by using the DiversiLab system (bioMérieux, La Balme-les-Grottes, France) according to the manufacturer's instructions. The genomic pattern of all isolates was identical ([Figure](#F1){ref-type="fig"}). Further multilocus sequence typing indicated that all isolates belonged to ST85. This ST was identified in Greece during a nationwide study that focused on carbapenem resistance in clinical isolates of *A. baumannii* and identified mainly carbapenem-hydrolyzing carbapenemase OXA-58 ([@R9]).

![Results of Diversilab system (bioMérieux, La Balme-les-Grottes, France) analysis of *Acinetobacter baumannii* isolates. Similarity line shows the cutoff that separates the different clones.](12-1618-F){#F1}

Recently, we showed that the *bla*~NDM-1~ gene was carried by a composite transposon bracketed by 2 copies of IS*Aba125* in *A. baumannii* ([@R10]). Cloning and sequencing of the genetic context of the *bla*~NDM-1~ in the first isolate showed that transposon Tn*125* was truncated at its 3′-end extremity by insertion sequence IS*Aba14*, giving rise to a truncated Tn*125* (ΔTn*125*). PCR mapping of all isolates showed that they possessed this truncated isoform of Tn*125*, which was therefore probably no longer functional.

The identification of several clinical *A. baumannii* isolates that possessed the *bla*~NDM-1~ gene and originated from North Africa, with no obvious link to the Indian subcontinent, strongly suggests that 1 NDM-producing *A. baumannii* clone is probably widespread in North Africa and that it might now act as a reservoir for NDM-1. This finding might indicate that control of spread of multidrug-resistant *A. baumannii* would have a primary role in controlling spread of NDM-1.

###### Technical Appendix

Clinical features of New Delhi metallo-β-lactamase--producing *Acinetobacter baumannii.*
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